Latest From Harbour BioMed
Private Company Edition: Kymera said it will take up to three programs into the clinic by next year. Also, three new life science funds recently launched, including a Gates Foundation-backed accelerator for COVID-19 treatments, and Cell Medica reemerges as Kuur with new funding for CAR-NKT therapies.
HanAll and Daewoong remain upbeat on dry eye candidate HL036 and are gearing up for a second Phase III US study despite the first missing its primary endpoint in just-released top-line results.
New markets are opening up for Indian firms and China appears to be the flavor of the season, but gaining a strong foothold there is not expected to be even "half as easy" as in the US.
The coming of summer has seen a flurry of executive changes in the Asia Pacific biopharma sector. BMS has named a new China GM amid a fierce immuno-oncology battle, Parexel Japan has a new president, and other personnel changes take place at Nippon Kayaku, Zai Lab and Harbour BioMed.
- Large Molecule
- Therapeutic Areas
- Immune Disorders
- Parent & Subsidiaries
- Harbour BioMed
- Senior Management
Jingsong Wang, MD, PhD, CEO
Mai-Jing Liao, PhD, SVP, Head, Bus. Dev.
Xiaoxiang Chen, MD, EVP, Head, Clin. Dev. & Reg. Science
- Contact Info
866 Halei Rd., Ste. 311
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.